Last reviewed · How we verify
Immunomodulatory drugs
At a glance
| Generic name | Immunomodulatory drugs |
|---|---|
| Also known as | IMiDs |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- OEDEMA PERIPHERAL
- Thrombocytopenia
- Nausea
- Fatigue
- Neutropenia
- Anaemia
- DIARRHOEA
- FATIGUE
- Headache
- PYREXIA
- Asthenia
Key clinical trials
- Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma (PHASE2)
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
- Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT (PHASE1, PHASE2)
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (PHASE1)
- Immunoprevention for High-risk Lung Lesions (PHASE2)
- Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (PHASE2)
- Topical Methotrexate vs Minoxidil for Localized Alopecia Areata (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunomodulatory drugs CI brief — competitive landscape report
- Immunomodulatory drugs updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI